Zevra Therapeutics (ZVRA) Q2 2026 Earnings
GAAP EPS of $0.14 includes $6.4 million in noncash fair value adjustments related to warrant liabilities and contingent value rights (CVR). Adjusted EPS of $0.25 excludes these items.
How Did ZVRA Stock React to Q2 2026 Earnings?
S&P 500 over the same 30 days: −0.34%.
Did ZVRA Beat Earnings? Q2 2026 Results
Yes. Zevra Therapeutics reported Q2 2026 earnings of $0.25 a share on Aug 5, 2026, beating the $0.16 consensus estimate by 56.3%. Revenue was $39.7M against a $33.9M estimate.
Zevra Therapeutics delivered a strong second-quarter performance for fiscal 2026, posting adjusted EPS of $0.25 against a consensus estimate of $0.08, a beat of 212.50%, as its rare-disease commercial franchise continued to build momentum. Net revenue reached $39.66 million, up 53.3% year over year, driven primarily by $30.20 million in MIPLYFFA net revenue for Niemann-Pick disease type C. The quarter's profitability reflected a meaningful operational turnaround, with income from operations swinging to $16.78 million from a loss of $71.04 million in the year-ago period, aided by sharply lower cost of goods and reduced SG&A spending. Zevra also ended the quarter debt-free, with $260.20 million in cash and investments, a balance sheet the company says is sufficient to fund strategic priorities without tapping capital markets. That financial strength will be tested on multiple fronts; European regulators issued a negative opinion on arimoclomol's marketing application, prompting a re-examination request and a securities investigation by plaintiffs' law firms, even as the U.S. business and the Phase 3 celiprolol program for Vascular Ehlers-Danlos Syndrome continue to advance.
- Strong MIPLYFFA commercial execution in the U.S. with 14 new prescription enrollment forms in Q2 2026, totaling 184 since launch
- 53% increase in total net revenue year-over-year
- Significant reduction in cost of product revenue from $12.4 million to $1.5 million (excluding intangible amortization)
- SG&A expenses decreased $4.2 million year-over-year due to lower professional fees and third-party spending
- Market access stable at 69% of covered lives
“Zevra delivered strong MIPLYFFA performance and further established the therapy as an important treatment option for people living with Niemann-Pick disease type C. These results reflect the strength of our U.S. commercial execution. Additionally, we are pursuing access to arimoclomol for people living with NPC in Europe, and we have submitted a request for the re-examination of our Marketing Authorisation Application. Our global Expanded Access Program remains active for eligible patients, reflecting our steadfast commitment to patients and families.”
Zevra Therapeutics CEO, on the earnings call
What Was Zevra Therapeutics's Outlook in Q2 2026?
Zevra believes its available financial resources of $260.2 million in cash, cash equivalents, and investments are sufficient to execute on its strategic priorities independent from the capital markets. The company expects continued FDA engagement in the second half of 2026 to explore pathways to accelerate clinical development of celiprolol for Vascular Ehlers-Danlos Syndrome. In Europe, the company has submitted a request for re-examination of its Marketing Authorisation Application for arimoclomol for NPC treatment.
ZVRA YoY Financials
| Metric | Q2 2026 | Q2 2025 | Year over year |
|---|---|---|---|
| Revenue | $39.7M | $25.9M | +53.3% |
| Operating Income | $16.8M | $7.5M | +123.6% |
| Net Income | $8.8M | $74.7M | −88.3% |
ZVRA Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.